Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.30 USD
-0.02 (-1.52%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
by Zacks Equity Research
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -15.63% and 7.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 100% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.
Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Marinus Pharmaceuticals (MRNS) points to an 113% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 183.3% in Marinus Pharmaceuticals (MRNS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
by Zacks Equity Research
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 19.74% and 18.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 83.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 90% and 6.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 18.75% and 9.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.